RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Nasiek to Its Board of Directors 

Glen Rock, N.J., January 22, 2024 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors.

Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society. He has been a practicing physician for the last 35 years. Since 2006, he has been the Managing Partner of Allied Neurology & Interventional Pain Practice, and since 2008, he has served as the Director of Anesthesiology at Hackensack Surgery Center. Dr. Nasiek is a leader specializing in non-surgical options for the treatment of spinal and non-spinal pain and is a pioneer in the use of innovative techniques in the cervical, thoracic and lumbar spine. His forward-looking approaches to pain management, regenerative medicine and tissue healing are described in the new 2nd Edition of his book entitled, “PRP, Platelet Rich Plasma: A New Paradigm in Regenerative Medicine.” 

“It is a pleasure to welcome Dr. Nasiek as a director on our board. He brings considerable value not only his status as an outside director, but the perspective that he provides because of his considerable clinical experience in the areas in which RespireRx is developing its compounds: treatment of respiratory disorders and spinal injury with our AMPAkine platform and the development of our GABAkines for use as non-narcotic analgesics and for treatment resistant epilepsy,” – said Arnold Lippa, Executive Chairman of the Board, Interim Chief Executive Officer, Interim President and Chief Scientific Officer. 

“I am pleased to join the RespireRx board of directors and look forward to contributing significantly based upon my extensive direct patient experience with most opportunities being developed by the company and my broader medical experience as well as my general medical and life science intellectual curiosity. I am excited about the science, the clinical development strategies and the potential breakthroughs for patient care,” – said Dr. Nasiek. 

About RespireRx Group:

RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and  

The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs. 

For additional information, please call or text:
Dariusz Nasiek, MD: tel. 201-894-1313, SMS: 973-773-7730
Allied Neurology & Interventional Pain Practice
Englewood Office: 185 Grand Ave. Englewood, NJ 07631
[email protected]


Victor M.
Best doctors i ever been too, i went one and never stopped going. His office is so clean and well organized, they are also very professional. Dr. Darius J. Nasiek is a great MD, he had no problem finding what is wrong and helping the area. I would recommend this place to everyone, if you don’t believe me see for yourself.
Alex Hernandez
Dr. Nasiek is a very knowledgeable physician who cares about his patients. I have worked with him for over ten years, and he gives patients many options. His facility is organized and up to date. He is also a great teacher and hosts valuable seminars I have attended. He is also the author of a second edition of the PRP book. You will feel comfortable and at ease with Dr. Nasiek.
A. Y.
Dr. Nasiek introduced me to PRP injections & the results have been nothing short of amazing. His deep knowledge in this field is evident & he patiently explained the procedure & its benefits every step of the way! Thank you Dr.Nasiek !
See all opinions
Dr. Nasiek specializes in Interventional Pain, identifying the source of pain and providing solutions with expertise in anesthesiology and Interventional Pain Practice.